Quadrant Capital Group’s NanoViricides NNVC Stock Holding History

Quadrant Capital Group’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-313	Closed	–	–	2213
2019 Q4	$0	Buy	+313	New	+$707	﹤0.01%	2465

Other funds holding NNVC

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HIS

Harvest Investment Services Oakbrook Terrace, Illinois $647M AUM 89.3% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Quadrant Capital Group's NNVC Position: Q1 2020 in Review

Quadrant Capital Group sold out of NanoViricides (NNVC) in Q1 2020, closing a stake of 313 shares.

Quadrant Capital Group first reported a position in NNVC in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 26 funds tracked by Wall St. Rank hold NNVC as of Q1 2020.

Quadrant Capital Group reported no remaining NanoViricides position as of Q1 2020 after selling out during the quarter.
Quadrant Capital Group sold 313 NanoViricides shares in Q1 2020.
Quadrant Capital Group first reported a position in NanoViricides in Q4 2019 and held it in 1 quarter.
Quadrant Capital Group's NanoViricides position peaked at $0 in Q4 2019.
26 funds tracked by Wall St. Rank held NanoViricides as of Q1 2020.

Based on Quadrant Capital Group's 13F filing for Q1 2020, filed 15 May 2020.